Stay updated on LGX818 and MEK162 With Third Agent in BRAF Melanoma Clinical Trial
Sign up to get notified when there's something new on the LGX818 and MEK162 With Third Agent in BRAF Melanoma Clinical Trial page.

Latest updates to the LGX818 and MEK162 With Third Agent in BRAF Melanoma Clinical Trial page
- Check10 days agoNo Change Detected
- Check17 days agoChange DetectedA new revision entry 'Revision: v3.6.6' was added to the study's record history, and the previous entry 'Revision: v3.6.5' was removed. This updates the record's version history to reflect the latest update.SummaryDifference0.1%

- Check24 days agoNo Change Detected
- Check38 days agoChange DetectedNew revision entry v3.6.5 is now shown in the record history, replacing the previous v3.6.4. This reflects an update to the page's revision/version information rather than substantive changes to the study data or content.SummaryDifference0.1%

- Check52 days agoChange DetectedA new revision entry (v3.6.4) was added to the study record history, replacing the previous (v3.6.3); this reflects an update to the history tracking on the ClinicalTrials.gov page.SummaryDifference0.1%

- Check74 days agoChange DetectedThe study history page shows a new revision label (v3.6.3) replacing the previous v3.6.2, indicating a small refresh to the page's revision history rather than a change to the study information.SummaryDifference0.1%

- Check81 days agoChange DetectedThe Study Record History now includes a new revision entry (v3.6.2) and removes the previous revision (v3.6.0), indicating an update to the page rendering or underlying system.SummaryDifference0.1%

- Check95 days agoChange DetectedThe history shows the study now indicates no longer looking for participants, signaling that enrollment has closed. The record version has been updated to v3.6.0, replacing the previous v3.5.5.SummaryDifference0.3%

Stay in the know with updates to LGX818 and MEK162 With Third Agent in BRAF Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the LGX818 and MEK162 With Third Agent in BRAF Melanoma Clinical Trial page.